2015 Guidance on cancer immunotherapy development in early‐phase clinical studies

E-ISSN： 1349-7006|106|12|1761-1771

ISSN： 1347-9032

Source： Cancer Science, Vol.106, Iss.12, 2015-12, pp. : 1761-1771

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy

Cancer Science, Vol. 106, Iss. 8, 2015-08 ,pp. : 945-950

John Wiley & Sons Inc

Access to resources Recommend Favorite

Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS‐PC Study

Cancer Science, Vol. 106, Iss. 7, 2015-07 ,pp. : 883-890

John Wiley & Sons Inc

Access to resources Recommend Favorite

Immunotherapy with CpG‐ODN in neoplastic meningitis: A phase I trial

Cancer Science, Vol. 106, Iss. 9, 2015-09 ,pp. : 1212-1218

John Wiley & Sons Inc

Access to resources Recommend Favorite

Immunotherapy with CpG‐ODN in neoplastic meningitis: A phase I trial

Cancer Science, Vol. 1347-9032, Iss. 9, 2015-09 ,pp. : 1212-1218

John Wiley & Sons Inc

Access to resources Recommend Favorite

Newcastle disease virus co‐expressing interleukin 7 and interleukin 15 modified tumor cells as a vaccine for cancer immunotherapy

Cancer Science, Vol. 109, Iss. 2, 2018-02 ,pp. : 279-288

John Wiley & Sons Inc

Access to resources Recommend Favorite